Výsledky vyhľadávania - "Imeglimin"

Long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52‐week postmarketing clinical study (TWINKLE)

Autori: Tetsuya Babazono Takeshi Osonoi Hideki Okamoto a ďalší

Zdroj: Journal of Diabetes Investigation, Vol 16, Iss 10, Pp 1808-1819 (2025)

Predmety: Imeglimin, Renal insufficiency, Type 2 diabetes, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

Popis súboru: electronic resource

Relation: https://doaj.org/toc/2040-1116; https://doaj.org/toc/2040-1124

Prístupová URL adresa: https://doaj.org/article/3a55171eaf824baf909e9ed3a35cfd89

Evaluation of Efficacy, Safety, and Tolerability of Imeglimin Hydrochloride SR Tablets 1000 mg in Participants with Inadequately Controlled Type 2 Diabetes Mellitus: A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Clinical Study from India

Autori: Prashant Kumthekar Mihir Upadhyay Vijay Kranti a ďalší

Zdroj: Journal of Diabetology, Vol 16, Iss 2, Pp 182-189 (2025)

Predmety: imeglimin hydrochloride, hba1c, monotherapy, sustained release, RC648-665, glycemic response, Diseases of the endocrine glands. Clinical endocrinology

Prístupová URL adresa: https://doaj.org/article/0facd348aea641fd9e63d16881bf8a28

Imeglimin, unlike metformin, does not perturb differentiation of human induced pluripotent stem cells towards pancreatic β‐like cells and rather enhances gain in β cell identity gene sets

Autori: Tasuku Imada Shugo Sasaki Hiroki Yamaguchi a ďalší

Zdroj: J Diabetes Investig
Journal of Diabetes Investigation, Vol 16, Iss 4, Pp 584-597 (2025)

Predmety: Imeglimin, Insulin-Secreting Cells, Induced Pluripotent Stem Cells, Humans, Hypoglycemic Agents, Cell Differentiation, Articles, β cell differentiation, RC648-665, Diseases of the endocrine glands. Clinical endocrinology, Metformin, Cells, Cultured

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39829307
https://doaj.org/article/649d61102639443ba95fbb740c6e0370

Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study

Autori: Atsushi Itsukaichi Fukumi Yoshikawa Ayako Fuchigami a ďalší

Zdroj: Diabetes Metab Syndr Obes
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 18, Pp 101-111 (2025)

Predmety: meal tolerance test, RC581-951, Clinical Trial Report, imeglimin, time in range, glycemic variability, dpp-4 inhibitor, Specialties of internal medicine, continuous glucose monitoring

Prístupová URL adresa: https://doaj.org/article/f1e1b865c82f4f7ebd4b2a23765f0d64

Imeglimin as an effective therapeutic approach in management of type 2 diabetes mellitus: an umbrella review and systematic review, meta-regression and meta-analysis

Autori: Qian Song Rui Mae Emad Kutbi a ďalší

Zdroj: Diabetology & Metabolic Syndrome, Vol 17, Iss 1, Pp 1-15 (2025)

Predmety: Imeglimin, Diabetes mellitus, Glycemic, Umbrella, Meta-analysis, Nutritional diseases. Deficiency diseases, RC620-627

Popis súboru: electronic resource

Relation: https://doaj.org/toc/1758-5996

Prístupová URL adresa: https://doaj.org/article/5404a8c851a044daa57bfaeb0b1e5dfa

Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort study

Autori: Abhishek Satheesan Janardanan Kumar Kakithakara Vajravelu Leela a ďalší

Zdroj: Frontiers in Endocrinology, Vol 16 (2025)

Predmety: Imeglimin, telomere length, glycemic control, mitochondrial DNA, type 2 diabetes, RC648-665, Diseases of the endocrine glands. Clinical endocrinology

Prístupová URL adresa: https://doaj.org/article/9ac20919edb74773ac7f0e22da644a3f

Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A post‐hoc analysis of imeglimin clinical trial data

Autori: Jumpei Ito Katsuhiko Hagi Kenji Kochi a ďalší

Zdroj: J Diabetes Investig
Journal of Diabetes Investigation, Vol 16, Iss 4, Pp 629-638 (2025)

Predmety: Male, Diarrhea, 0301 basic medicine, 0303 health sciences, Gastrointestinal Diseases, Triazines, Articles, Middle Aged, RC648-665, Prognosis, Gastrointestinal symptoms, Diseases of the endocrine glands. Clinical endocrinology, Metformin, 03 medical and health sciences, Diabetes Mellitus, Type 2, Imeglimin, Humans, Hypoglycemic Agents, Female, Drug Therapy, Combination, Combination therapy, Aged, Follow-Up Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39723797
https://doaj.org/article/f1956e07476c445e8c2904fbde259e65

Elevated Serum Growth Differentiation Factor 15 Levels as a Potential Biomarker of the Efficacy of Imeglimin in Individuals With Type 2 Diabetes Mellitus: An Exploratory Study

Autori: Naoki Wada Takaaki Murakami Muhammad Fauzi a ďalší

Prispievatelia: Naoki Wada Takaaki Murakami Muhammad Fauzi a ďalší

Zdroj: J Clin Med Res

Predmety: GDF15, Diabetes mellitus, Imeglimin, Short Communication

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39544328

Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial

Autori: Takeshi Osonoi Shinichiro Shirabe Miyoko Saito a ďalší

Zdroj: Frontiers in Endocrinology, Vol 16 (2025)

Predmety: imeglimin, HbA1c, glycoalbumin, hemoglobin, erythrocyte lifespan, type 2 diabetes, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

Popis súboru: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fendo.2025.1699591/full; https://doaj.org/toc/1664-2392

Prístupová URL adresa: https://doaj.org/article/19836cfaf1844c68a09c5e26476e719f

Green bioanalytical method development and validation for estimation of Imeglimin hydrochloride using human plasma in pure form by LC–MS/MS

Autori: Chandni V. Chandarana Vidhi H. Vashi Anjana Bera a ďalší

Zdroj: Future Journal of Pharmaceutical Sciences, Vol 11, Iss 1, Pp 1-10 (2025)

Predmety: Imeglimin hydrochloride, LC–MS/MS, Bioanalytical method validation, Human plasma, Diabetes, Therapeutics. Pharmacology, RM1-950, Pharmacy and materia medica, RS1-441

Popis súboru: electronic resource

Relation: https://doaj.org/toc/2314-7253

Prístupová URL adresa: https://doaj.org/article/3eba8fc7a9f94043b2d56aa8f30e7a6b

Development and Validation of HPLC Method for Determination of an API in Presence of its Degradation Products

Autori: Shraddha Muneshwar, Sohan Thipe, Amol Sawale, Shailesh Jawarkar

Predmety: Imeglimin, Diabetes, HILIC, Validation, Forced Degradation

Imeglimin-based therapies improve glycemic control and reduce mitochondrial stress in type 2 diabetes: a prospective cohort study

Autori: Abhishek Satheesan Janardanan Subramonia Kumar Leela Kakithakara Vajravelu a ďalší

Zdroj: Frontiers in Endocrinology, Vol 16 (2025)

Predmety: Imeglimin, type 2 diabetes mellitus, ccf-mtDNA, NLRP3 inflammasome, HbA1c, oral hypoglycemic agents, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

Popis súboru: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fendo.2025.1639046/full; https://doaj.org/toc/1664-2392

Prístupová URL adresa: https://doaj.org/article/3b827bc23f2e4eada875b8db5b60b4bc

Imeglimin suppresses glucagon secretion and induces a loss of α cell identity

Autori: Takahiro Tsuno Jinghe Li Kuniyuki Nishiyama a ďalší

Zdroj: Cell Reports Medicine, Vol 6, Iss 8, Pp 102254- (2025)

Predmety: α cells, glucagon, human islets, imeglimin, C/EBP homologous protein, MafB, Medicine (General), R5-920

Popis súboru: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666379125003271; https://doaj.org/toc/2666-3791

Prístupová URL adresa: https://doaj.org/article/dcfedb6fe14344f48538ba4ff36a31df

The distinct effects of metformin and imeglimin on high glucose-induced alterations in metabolic function and reactive oxygen species production in mouse Schwann cells are modulated by pemafibrate and/or fatty acid-binding proteins.

Autori: Hiroshi Ohguro Megumi Higashide Nami Nishikiori a ďalší

Zdroj: Frontiers in Cellular Neuroscience, Vol 19 (2025)

Predmety: Schwann cells, metformin, imeglimin, FABP5, FABP7, extracellular flux analyzer, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571

Popis súboru: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fncel.2025.1634262/full; https://doaj.org/toc/1662-5102

Prístupová URL adresa: https://doaj.org/article/e260646deae34a00a09ceda27d53c83b

Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice

Autori: Osamu Kikuchi Yuichi Ikeuchi Masaki Kobayashi a ďalší

Zdroj: J Diabetes Investig
Journal of Diabetes Investigation, Vol 15, Iss 9, Pp 1177-1190 (2024)

Predmety: Male, Blood Glucose, 0301 basic medicine, 0303 health sciences, Triazines, Articles, Glucose Tolerance Test, RC648-665, Diet, High-Fat, Glucagon, Diseases of the endocrine glands. Clinical endocrinology, 3. Good health, Fatty Liver, Mice, Inbred C57BL, Glucagon‐like peptide‐1, Mice, 03 medical and health sciences, Glucagon-Secreting Cells, Glucagon-Like Peptide 1, Dietary Sucrose, Imeglimin, Animals, Insulin, Hypoglycemic Agents, Insulin Resistance

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38874179
https://doaj.org/article/b421d60f1b0b47b1858c0736d304e692

Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study

Autori: Itsukaichi A Yoshikawa F Fuchigami A a ďalší

Zdroj: Diabetes, Metabolic Syndrome and Obesity, Vol 18, Pp 101-111 (2025)

Predmety: imeglimin, dpp-4 inhibitor, time in range, glycemic variability, continuous glucose monitoring, meal tolerance test, Specialties of internal medicine, RC581-951

Popis súboru: electronic resource

Relation: https://www.dovepress.com/effect-of-imeglimin-a-novel-anti-diabetic-agent-on-insulin-secretion-a-peer-reviewed-fulltext-article-DMSO; https://doaj.org/toc/1178-7007

Prístupová URL adresa: https://doaj.org/article/f1e1b865c82f4f7ebd4b2a23765f0d64

Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus

Autori: Katsuhiko Hagi Kenji Kochi Hirotaka Watada a ďalší

Zdroj: J Diabetes Investig
Journal of Diabetes Investigation, Vol 15, Iss 9, Pp 1239-1247 (2024)

Predmety: Adult, Male, Blood Glucose, Glycated Hemoglobin, Triazines, East Asian People, Articles, Middle Aged, Treatment response, Type 2 diabetes mellitus, RC648-665, Diseases of the endocrine glands. Clinical endocrinology, 3. Good health, 12. Responsible consumption, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Diabetes Mellitus, Type 2, Double-Blind Method, Japan, Imeglimin, Humans, Hypoglycemic Agents, Female, Aged

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38794986
https://doaj.org/article/acbd42a80493459ca76f7b60103bec63

QBD (QUALITY BY DESIGN) APPROACH: DEVELOPMENT AND VALIDATION OF AN RP-HPLC METHOD FOR ESTIMATING IMEGLIMIN HCL AND ITS KETONE IMPURITY

Autori: GIRI, POOJA T. CHABUKSWAR, ANURUDDHA R. JAGDALE, SWATI C. a ďalší

Zdroj: International Journal of Applied Pharmaceutics; Vol 17, Issue 4 (Jul-Aug), 2025; 241-253 ; 0975-7058

Predmety: Imeglimin hydrochloride, Imeglimin ketone impurity, Quality by design (QBD), RP-HPLC, Central composite design

Popis súboru: application/pdf; text/html

Relation: https://journals.innovareacademics.in/index.php/ijap/article/view/54506/32273; https://journals.innovareacademics.in/index.php/ijap/article/view/54506/32357; https://journals.innovareacademics.in/index.php/ijap/article/view/54506

Dostupnosť: https://journals.innovareacademics.in/index.php/ijap/article/view/54506

Safety and Efficacy of Imeglimin in Type 2 Diabetes Individuals with Metformin Intolerance: A Case-Control Study

Autori: Prabhat Agrawal Ashish Gautam Chandra Prakash a ďalší

Zdroj: Clinical Diabetology, Vol 14, Iss 3 (2025)

Predmety: imeglimin, HbA1c, metformin intolerance, safety, Medicine

Popis súboru: electronic resource

Relation: https://journals.viamedica.pl/clinical_diabetology/article/view/104962; https://doaj.org/toc/2450-7458; https://doaj.org/toc/2450-8187

Prístupová URL adresa: https://doaj.org/article/03b1fb15ed9743a99756dc84fe42eb02

Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

Autori: Sumitomo Pharma Co., Ltd. Kohjiro Ueki, Director, Diabetes Research Center, Research Institute

Prispievatelia: Sumitomo Pharma Co., Ltd. Kohjiro Ueki, Director, Diabetes Research Center, Research Institute

Zdroj: Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus: a Multicenter, Open-label, Randomized, Controlled Trial (DIGNITY Trial)